Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.47 |
| ▸ | GRM5 | P41594 | 11/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607952 | 0.93 | KIT (0.49) | HTR6GRM1GRM5PDK4KIT | |
| SCHEMBL15525366 | 0.93 | KIT (0.49) | HTR6GRM1GRM5PDK4KIT | |
| SCHEMBL16040458 | 0.86 | HTR6 (0.51) | HTR6GRM1GRM5PDK4GPR119 | |
| SCHEMBL16048880 | 0.85 | CCNT1 (0.39) | HTR6GRM1GRM5 | |
| SCHEMBL4318186 | 0.85 | HTR6 (0.53) | HTR6GRM1GRM5PDK4GPR119 | |
| SCHEMBL23121219 | 0.83 | EGLN1 (0.39) | KIT | |
| SCHEMBL16049042 | 0.82 | HTR6 (0.48) | HTR6GRM1GRM5KIT | |
| SCHEMBL16035864 | 0.82 | KIT (0.46) | HTR6GRM1GRM5PDK4KIT | |
| SCHEMBL16039939 | 0.81 | HTR6 (0.51) | HTR6GRM1GRM5PDK4 | |
| SCHEMBL16048735 | 0.81 | HTR6 (0.47) | HTR6GRM1GRM5PDK4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346813-B2 | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2970268-A1 | CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-8969375-B2 | CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2014159999-A1 | CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | ABBIVE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275004-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| CN-101052629-A | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARM INC (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | HTR6 2912/4885GRM1 842/4885GRM5 1387/4885 |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK10 | HTR6 3953/4885GRM1 2697/4885GRM5 3128/4885 |
| US-20140275004-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | HTR6 3870/4885GRM1 1805/4885GRM5 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.